Canal Therapeutics is a new startup to develop novel analgesics through precise regulation of ion channels. Backed by both human genetics and animal model data, the strategy of harnessing ion channel biology has emerged as a powerful modality to treat refractory pain. However, almost all current treatments for pain are systemic, while most severe pain conditions are focal. Using state of the art gene therapy techniques, Canal leverages both spatial and cell-type precision to treat severe pain. The company’s first program is an AAV9-based gene therapy for the initial indication of painful neuroma.